Context Therapeutics (CNTX) Capital Expenditures (2022 - 2026)

Context Therapeutics has disclosed Capital Expenditures across 4 years of filings, most recently posting $37258.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $37258.0, up 9.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $37258.0 (down 9.71% YoY), and the FY2025 annual result was $33948.0, up 364.02% from the prior year.
• Capital Expenditures came in at $37258.0 for Q1 2026 at Context Therapeutics, up from $33948.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $37258.0 in Q1 2026 to a low of $1837.0 in Q2 2022.
• The 4-year median for Capital Expenditures is $33948.0 (2025), against an average of $23071.6.
• Peak annual rise in Capital Expenditures reached 9.75% in 2026, while the deepest fall reached 9.75% in 2026.
• Context Therapeutics' Capital Expenditures stood at $1837.0 in 2022, then jumped by 298.26% to $7316.0 in 2024, then soared by 364.02% to $33948.0 in 2025, then advanced by 9.75% to $37258.0 in 2026.
• The last three Capital Expenditures figures came in at $37258.0 (Q1 2026), $33948.0 (Q1 2025), and $7316.0 (Q3 2024), per Business Quant data.